Introduction The androgen receptor (AR) is widely expressed in breast cancers and has been
proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers …

The transcription factor ZEB1 is normally not expressed in epithelial cells. When inappropriately
expressed in carcinomas, ZEB1 initiates epithelial to mesenchymal transition due to its …

Introduction miR-200c and other members of the miR-200 family promote epithelial identity
by directly targeting ZEB1 and ZEB2, which repress E-cadherin and other genes involved in …

We focus on unique roles of miR-200c in breast, ovarian, and endometrial cancers. Members
of the miR-200 family target ZEB1, a transcription factor which represses E-cadherin and …

To identify microRNAs (miRNAs) associated with estrogen receptor (ESR1) status, we profiled
luminal A, ESR1+ breast cancer cell lines versus triple negative (TN), which lack ERα, …

Brain metastasis (br-met) develops in an immunologically unique br-met niche. Central
nervous system-native myeloid cells (CNS-myeloids) and bone-marrow-derived myeloid cells (…

Carcinogenesis is a complex process during which cells undergo genetic and epigenetic
alterations. These changes can lead tumor cells to acquire characteristics that enable …

A therapeutic intervention that could decrease tumor burden and increase sensitivity to
chemotherapy would have a significant impact on the high morbidity rate associated with ovarian …

The female hormone progesterone (P4) promotes the expansion of stem-like cancer cells in
estrogen receptor (ER)-and progesterone receptor (PR)-positive breast tumors. The …

The anti-diabetic drug metformin (1,1-dimethylbiguanide hydrochloride) reduces both the
incidence and mortality of several types of cancer. Metformin has been shown to selectively kill …